A new ad from the Coca-Cola Co. opens with a shot of a typewriter clacking out Stephen King’s The Shining. The viewer follows ...

Mechanically, the Manufaktur Editions are unchanged from the regular AMG CLE53. That means they are powered by a ...

As one of our resident wardrobe-basics experts, I’ve learned that a good white T-shirt is easy to find, but a truly great one — one that hits the marks on comfort and durability as well as ...

It typically lasts up to six weeks and starts as bright red blood before gradually becoming lighter in color—first pink, then brown, and finally yellow or white. If the flow is slow, the blood may ...

2-Year U.S. Treasury Note Continuous Contract $103.672 0.086 0.08% 5-Year U.S. Treasury Note Continuous Contract $108.445 0.289 0.27% 10-Year U.S. Treasury Note Continuous Contract $111.734 0.516 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

SPOILERS: This post contains details about the White Lotus, Season 3 episode ‘Denials’ As this season of The White Lotus continues to push the limits of Mike White’s imagination, a ...

The university claims using the logo in the scene "simply goes too far." By Lexi Carson [The following story contains spoilers from the latest episode of The White Lotus, “Denials.”] ...

This feels like it's another stepping stone to Daredevil's classic red suit, logo and all. As for why he's currently all in black, chances are it's to go incognito with Mayor Fisk and his Anti ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...